Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LILLY PAC CONTRIBUTORS $94,000 IN 1984, HIGHEST AMOUNT AMONG CROSS-SECTION OF DRUG FIRMS REPORTING TO FEC; MERCK GIVES $40,000 IN THIRD QUARTER

Executive Summary

Lilly's 1984 contributions to candidates for political office reached $93,718 through August, making the firm's political action cmte. (PAC) the top contributor among pharmaceutical company PACs in an informal sampling of Federal Election Commission reports by "The Pink Sheet." The Lilly PAC gave most of its 1984 campaign contributions during the last three months for which it has filed reports, June-August. In June the company almost doubled its disbursements for the year, contributing $20,675 during the month for a total of $46,068. In July the PAC contributed another $29,900 and in August added $17,750 to its total disbursements. Merck followed Lilly, contributing $69,336 in PAC disbursements through September of 1984. Merck gave $40,350 in the third quarter, from July 1-Sept. 30. The third highest total was contributed by the Abbott Laboratories Better Govt. Fund, which gave $61,485 through August. President Reagan's re-election campaign has received $8,000 from Lilly. The PAC gave Indiana's Reagan/Bush Cmte. $1,500 in March and $3,500 in May. Additionally, Lilly contributed $3,000 to the President's Dinner Cmte. on March 16. Sen. Thurmond's Re-election Bid Receives $4,500 In Third-Quarter Contributions From Drug PACs Sen. Armstrong (R-Colo.) received $5,000 from Lilly on Aug. 6. A fiscal conservative who was first elected in 1978 on the appeal for less govt., Armstrong is considered an effective legislator. Although he is in his first bid for re-election, a recent Denver Post poll indicated he is leading his opponent Colorado Lieutenant Gov. Nancy Dick by 25 percentage points. Armstrong sits on the Senate Finance Cmte.; he is the Budget/Social Security & Income Maintenance Programs Subcmte. chairman; and he chairs the Banking, Housing & Urban Affairs Cmte.'s Financial Institutions subcmte.In addition, he is a member of the Governmental Affairs Cmte. Among Indiana political races, the Lilly PAC contributed $4,000 to the re-election campaign of Gov. Bob Orr, who is seeking his second term. Sen. Quayle (R), whose first term does not expire until 1986, received $1,000. Lilly also contributed to the campaigns of the following U.S. representatives from Indiana: Republicans Costs ($1,500), Hiler ($1,500), Burton ($1,000), Hillis ($1,000), and Myers ($1,000); and Democrats Hamilton ($750) and Sharp ($125). Other candidates for re-election who received Lilly contributions this year include the following: Sens. Boschwitz (R-Minn.), Cochran (R-Miss.), and Humphrey (R-N.H.) each received $3,000. Several senators and congressmen received $1,000 in Lilly contributions this year, including Sens. Helms (R-N.C.), Bradley (D-N.J.), Domenici (R-N.M.), Kassebaum (R-Kan.), Nunn (D-Ga.), Jepsen (R-Iowa), Pressler (R-S.D.), Thurmond (R-S.C.); and Reps. Luken (D-Ohio), Rostenkowski (D-Ill.), Foley (D-Wash.), Vander Jagt (R-Mich.), Jones (D-Tenn.), and Madigan (R-Ill.). The Merck PAC's largest third quarter contributions to political candidates went to former Rep. Gramm (R-Texas) and former astronaut Jack Lousma (R-Mich.), who are running for the Senate; Sens. Percy (R-Ill.)and Biden (D-Del.); and congressional candidate Jim Ross Lightfoot (R-Iowa), a broadcaster who is running for the House seat vacated by Rep. Harkin (D), who resigned to run for the Senate. Each of the candidates received $1,000 from Merck during the quarter; several other candidates for Congress received contributions of $500 or less from the PAC. Merck's largest disbursement during the quarter was a total of $13,550, which was transferred to Merck state PACs in California, New Jersey, and Pennsylvania. In addition to contributions to the congressional races Merck reported during the quarter, the PAC gave $600 on Sept. 26 to Puerto Rican Gov. Romero. Bristol-Myers also contributed $500 to Romero, who is seeking his third term in office. Merck and B-M are two of several pharmaceutical firms with operations on the island. Other firms whose PACs contributed the highest totals during 1984 included J&J's Good Govt. Fund ($53,000 thru June), SmithKline's PAC ($51,000 through August), B-M's PAC ($50,000 through August), Pfizer's PAC ($43,000 through June), Roche's Good Govt. Cmte. ($30,000 through August), and Dupont's Good Govt. Fund ($25,000 through August). The NACDS PAC contributed $17,000 through June, NARD's Natl. Assn. of Pharmacists PAC gave $8,134 through June, P-A PAC disbursements totaled $3,500 through June, and PMA's Better Govt. Fund contributed $2,500 through September. Sen. Thurmond (R-S.C.), who sits on the Senate Labor & Human Resources Cmte. and chairs the Judiciary Cmte., has received $4,500 during the most recent three months in which the sampled PACs filed reports with the FEC. Thurmond is running for his sixth term. During the same period, Sen. Pell (D-R.I.), who also sits on Labor & Human Resources and is seeking a fifth term, received $250 from Ciba-Geigy. Cmte. Chairman Hatch (R-Utah) received $1,160 in contributions from the PACs even though he is not up for re-election until 1988. Rep. Madigan Receives $3,660: Highest Total Among Members of Health-Related House Cmtes. Only one other cmte. member would have been up for re-election this year: Sen. Randolph (D-W.Va.), who has retired. A possible candidate for Randolph's place on the cmte. is Rep. Gore (D-Tenn.), who is battling Republican Victor Ashe for the Senate seat vacated by the retirement of Tennessee Sen. Baker (R). Gore received no contributions during the period from the sample PACs, whereas Ashe received $1,000 in contributions. Gore is currently leading his opponent by a confortable margin ("The Pink Sheet" Oct. 15, p. 7). Rep. Madigan (R-Ill.) led all House members receiving contributions during the three months from the PACs sampled, with $3,660 in receipts. Madigan is the ranking minority member of the Commerce/Health Subcmte. Another subcmte. member, Rep. Bliley (R-Va.), received $2,782 in contributions. Rep. Waxman (D-Calif.), who chairs the subcmte., received $2,330. Another minority member of Waxman's subcmte., Rep. Luken (R-Ohio), received $2,298. The next highest total -- $1,650 -- was contributed to Rep. Hughes. The New Jersey Democrat does not sit on a health subcmte., but as Judiciary/Crime Subcmte. chairman he was instrumental in formulating legislation of interest to the industry, including the Pharmacy Crime Bill and the Dangerous Drug Diversion provisions of the recently passed crime package. The smallest listed contribution during the period was $10 given to Rep. Ratchford (D-Conn.) by constituent company Richardson-Vicks on Aug. 29. Ratchford sits on the Health & Long-Term Care Subcmte. of the House Select Cmte. on Aging. Chart omitted.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel